Product Wiki · Recalls · EU Safety Gate (RAPEX)

Kit de peinture au doigt drôle avec tampons fournitures de peinture… — recall A12/00585/24

EU Safety Gate (RAPEX) · France · 2024-03-08 · Serious risk

As described by EU Safety Gate (RAPEX): Kit de peinture au doigt drôle avec tampons fournitures de peinture pour les tout-petits

Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked on this page. No AI-generated text appears on this page. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/00585/24
Date of alert
2024-03-08
Country / jurisdiction
France
Risk level
Serious risk
Risk type
Chemical, Choking
Product category
Toys
Product type
Finger painting kit
Reported risk: The product contains methylisothiazolinone (MI) and methylchloroisothiazolinone (MCI). MI and MCI are strong sensitisers and can provoke allergic contact dermatitis in sensitised persons. Moreover, the foam of the ink pads and the plastic covers tear easily. A small child may put them in the mouth and choke.
What to do

Check whether your product matches this notice (name, batch, dates). If it does, stop using it and follow the instructions in the official notice — refund, return, repair or disposal are set by the issuing authority and the business, and they differ per recall. Official notice from EU Safety Gate (RAPEX) →

Action taken by the authority
Type of economic operator taking notified measure
Other
Category of measure
Removal of this product listing by the online marketplace
Date of entry into force
13/11/2023
Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10011226

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.